Vitiligo pathogenesis is interlinked with pigment homeostasis: A new concept
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Global research to resolve the mystery of vitiligo has been progressing in several directions, resulting in divergent data. 1 Such jigsaw pieces when integrated in to a comprehensive overview suggest that vitiligo is an outcome of a localized or generalized intrinsic malady of melanocytes that may evoke immune reactivity and thereby suffer destruction. 2 As melanocytes belong to the long arms of a centrally operating pigment homeostatic system, any pathology that involves melanocytes has to be considered in the larger context of their origin, survival, and replacement. In the light of this new perspective, current concepts are reviewed and course corrections suggested for future research.
Diagnosis and Clinical Types
Although many clinical patterns of vitiligo have been identified, consensus is achieved only in cases of generalized vitiligo with lesions in bilateral symmetric patterns either acral or trunk dominant; and segmental vitiligo, when lesions are confined to one small or large anatomical segment. Single lesions with well-defined margins usually associated with leukotrichia are considered as focal vitiligo. 2 The diagnosis becomes contentious with other patterns, which can be difficult to differentiate from post inflammatory depigmentation seen in several diseases. 3 The current practice is to classify vitiligo as segmental, non-segmental, or mixed types. [4] [5] [6] However, in the light of our recent data indicating anatomical segmentations in all forms of vitiligo, it would be more appropriate to consider vitiligo as mono segmented, bilateral multi segmented and a universal disease. 2
Pathogenesis
Anatomical segmentation when considered along with melanocytorrhagy (intrinsic anchoring and survival problems of melanocytes) [7] [8] [9] [10] [11] [12] suggests that the clinical expression of vitiligo is a mosaic developmental malady. Many extrinsic and intrinsic adverse factors may cut short the life span of such abnormal melanocytes necessitating their rapid turnover, which may in turn, enhance the risk of exposing immunogenic melanocyte-differentiating antigens. 13 The clinical expression of vitiligo depends upon the number of defective mosaics and the nature/severity of immune reaction-localized or disseminated. [14] [15] [16] [17] This hypothesis [ Figure 1 ] is supported by the association of vitiligo with halo nevi and melanoma immunotherapy. [18] [19] [20] [21] [22] [23] [24] Vitiligo and nevi, both considered as mosaic malformations (structural and/ functional) of melanocytes, 25,2 may evoke similar immune reactions against melanocyte antigens, albeit with different outcomes: depigmentation in vitiligo or resorption in the case of pigmented nevi. Interestingly, both these phenomena are seen together in halo nevi. The unique circular segmentations akin to the small circular anatomical segments seen in vitiligo [ Figure 2 ], indicate that the pigmented nevus along with its halo area may represent a combined mosaic defect of melanocytes (structural and/or functional), brought to clinical notice by the immune reaction against shared antigens. Ultimately, normal pigmented skin replaces the halo as well as the nevus; a unique phenomenon where defective mosaics are repaired by pigment homeostatic mechanisms. In some instances, common pigmented nevi may de novo provoke limited immune reactions resulting in the resorption of the nevi. We have also observed for the first time, a giant congenital nevus provoking generalized vitiligo in a middle-aged patient [ Figure 3 ]. This was not a mere association, as the depigmentation initially occurred only along the nevus (which was distributed along Blaschko's lines), but subsequently disseminated to normal pigmented skin in other areas. This suggests that immune reactions can arise anytime and become proactive beyond the nevus. Biopsies taken from the pigmented nevus and the adjacent depigmented skin demonstrated destruction of nevus nests due to lymphocytic infiltration around basal melanocytes, as seen in vitiligo. On the other hand, we have also observed halo nevi appearing along with or consequent to disseminated vitiligo, some of which failed to regain pigment even after the nevus disappeared. This may be because the immune reaction in generalized vitiligo not only destroys the pigmented nevus, but at the same time opposes the melanocyte recovery by normal pigment homeostasis. It would be interesting to study the fate of common pigmented nevi in patients suffering from universal vitiligo.
Insidious and fulminate types of evolution
Immune reactions in vitiligo can be localized or generalized, insidious, or fulminate. The most commonly seen acral disease with bilateral segmented lesions has an insidious onset with limited involvement. The lesions may resolve spontaneously or while remaining stable for long periods [ Figure 4 ], progress incrementally towards the trunk. Acral disease usually responds poorly to treatment. 26 A possible explanation could be that the longer migratory paths not only increase the risk of melanocytorrhagy, but also hinder pigment recovery. 2 Failure to cope with the localized but persisting immune reaction which increases the demand for melanocyte replacements, may result in centripetal extension of depigmentation. In contrast, fulminate generalized disease may arise from a de novo generalized autoimmune reaction, overwhelming the pigment homeostatic mechanism. Future studies need to test different hypothesis offered in these two distinct forms of vitiligo to explain the differences in their evolution and behaviour.
Pigment homeostasis
Steady streaming of melanocyte precursors along innumerable migratory pathways, arising from stem cell pools is probably a life time physiological feature to replace affected melanocytes. 2 Such a homeostatic mechanism becomes seriously compromised when melanocyte differentiating antigens become the target of immune reactions, thus blocking the final conversion of melanoblast to melanocyte. This hypothesis explains discordant reports-presence or absence of functional melanocytes in vitiligo, 27, 28 as the dynamic balance between the two opposing forces (immune reaction and melanocyte migration along bilateral symmetrical paths) may shift one way or the other at different periods. The initial pigment loss from acral areas and recovery in the opposite direction (as mirror image progression and regression), adds support to such a hypothesis. Pigment loss and recovery patterns in vitiligo indicate persistence of stem cell niches at all the anatomical junctional areas through which the melanocytes migrate. Stem cells in the follicular bulge are known to control the follicular-epidermal paths and when affected, result in punctate depigmentation in progressive disease [ Figure 5 ] and punctate repigmentation in the regressive phase [ Figure 6 ]. Vitiligo with the exception of fulminate disease, does not involve all the anatomical segments at the same time. Therefore, progressive, stable, and regressive lesions can be concurrently seen in different anatomical areas. This common observation indicates presence of independent stem cell niches within each anatomical segment. On the other hand, bilateral anatomical segments showing progression and regression in perfect unison suggest presence of stem cell pools at the dorsal midline of the body. This is exemplified in some cases of long standing universal vitiligo with pigment recovering in bilateral symmetrical waves [ Figure 7 ]. This gives the impression of fresh melanocyte migrations gaining over quiescent immune reactivity. Such migrations appear to override the follicular stem cell niche which usually induces spotty repigmentation [ Figure 6 ].
Several studies elucidated the role of immune reactions in vitiligo, but not much is known about pigment homeostatic mechanisms; in particular, information on the natural life span and replacement of melanocytes in the epidermis. There are reports of keratinocytes playing a predominant role in the homeostatic regulation of melanocytes within the epidermis and they might also be implicated in the regulation of melanocyte stem cells. Additionally, dermal fibroblasts are also believed to be involved in melanocyte regulation. How melanocyte stem cells are regulated by cells in other lineages is unclear, with the molecular mechanisms remaining elusive. 29 Although clinical observations indicate presence of melanocyte stem cell niches along the migratory paths at multiple levels, locations other than the follicular bulge are yet to be explored. The role of the human pituitary gland and alpha-MSH in pigment regulation is uncertain. [30] [31] [32] [33] Melanocyte precursors have been reported in the follicular bulge, infundibulum, and inter follicular epidermis in cases of vitiligo treated with narrow band ultraviolet light, indicating activated peripheral stem cell migration. 34 At a higher level, bolstering of Wnt signalling which can induce common origin cells to shift from the neural lines to the melanocytic lineage; [35] [36] [37] and c-kit receptors that are reported to enhance melanocyte migrations to the skin, 38 may offer new avenues for treatment.
Conclusions
Depigmentation in vitiligo is proposed as an outcome of a dynamic tug of war between the immune system (destroying developmentally defective melanocytes) and the pigment homeostatic mechanism (which is counteracting by providing melanocyte replacements). This concept depends upon the assumption of anatomical mosaic defects (melanocytorrhagy), which need to be investigated in all forms of vitiligo. The suggested role of pigment homeostasis based upon clinical evidence, can be considered speculative. Nevertheless, it should stimulate researchers to investigate and identify stem cell locations and their biological control mechanisms, beyond the follicular units.
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